Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking

Journal of Endocrinological Investigation

Volumn 37, Issue 4, 2014, Pages 331-338

  Labuz Roszak B ^a   Pierzchala K ^a   Tyrpien K ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acetylsalicylic acid; Aspirin resistance; Diabetes mellitus; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPIRIN RESISTANCE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG SENSITIVITY; FEMALE; HEART RATE; HEMATOCRIT; HUMAN; HYPERTENSION; LABORATORY TEST; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; WHOLE BLOOD IMPEDANCE AGGREGOMETRY; ADVERSE EFFECTS; BLOOD; COMPLICATION; DRUG RESISTANCE; HYPERLIPIDEMIA; LEUKOCYTE COUNT; MIDDLE AGED; THROMBOCYTE COUNT;

AGED; ASPIRIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; FEMALE; HEMATOCRIT; HUMANS; HYPERLIPIDEMIAS; LEUKOCYTE COUNT; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLATELET COUNT; SMOKING;

EID: 84900545002     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-013-0012-2     Document Type: Article

References (49)

1. Pignone M, Alberts MJ, Colwell JA et al (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes. JACC 55:2878-2886
2. Belch J, MacCuish A, Campbell I et al (2008) The prevention of progression of arterial disease and diabetes POPADAD trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease (abstract). BMJ 337:1840
3. Ogawa H, Nakayama M, Morimoto T et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300:2134-2214
4. Leung WY, So W, Steward D et al (2009) Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients - a longitudinal observational study. Cardiovasc Diabetol 8:57-67
5. Perk J, Backer G, Gohlke H et al (2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts): European guidelines on cardiovascular disease prevention in clinical practice: executive summary (version 2012). Eur Heart J 33:1635-1701
6. Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987-1003
7. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
8. Berrouschot J, Schwetlick B, von Twickel G et al (2006) Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 113:31-35
9. Seok JI, Joo IS, Yoon JH et al (2008) Can aspirin resistance be clinically predicted in stroke patients? Clin Neurol Neurosurg 110:110-116
10. Bernstein PL, Jacobson BF, Connor MD, Becker PJ (2009) Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. J Neurol Sci 277:80-82
11. Zytkiewicz M, Gielwanowska L, Wojtasinska E, Psuja P, Zawilska K (2008) Resistance to acetylsalicylic acid in patients after ischaemic stroke. Pol Arch Med Wewn 118:727-732
12. Postula M, Tarchalska-Krynska B, Filipiak KJ et al (2010) Factors responsible for aspirin resistance - can we identify them? Kardiol Pol 68:412-413
13. Karepov V, Tolpina G, Kuliczkowski W, Serebruany V (2008) Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischaemic stroke. Cerebrovasc Dis 26:272-276
14. Bennet D, Yan B, Macgregor L, Eccleston D, Davis SM (2008) A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci 15:1204-1209
15. Zimmermann N, Hohlfeld T (2008) Clinical implications of aspirin resistance. Thromb Haemost 100:379-390
16. Ertugrul DT, Tutal E, Yildiz M et al (2010) Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab 95:2897-2901
17. Watala C, Golanski J, Pluta J et al (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) - its relation to metabolic control. Thromb Res 113:101-113
18. Fitzgerald R, Pirmohamed M (2011) Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Therap 130:213-225
19. Cohen HW, Crandall JP, Hailpern SM, Billett HH (2008) Aspirin resistance associated with HbA1C and obesity in diabetic patients. J Diabetes Complicat 22:224-228
20. Fateh-Moghadam S, Plockinger U, Cabeza N et al (2005) Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99-103
21. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB (2006) Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567-570
22. Toth O, Calatzis A, Penz S, Losonczy H, SiessW (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96:781-788
23. Paniccia R, Antonucci E, Maggini N et al (2009) Assessment of platelet function on whole blood by multiplate electrode platelet aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 131:834-842
24. Calatzis A, Spannagl M, Loreth R (2007) Multiplate platelet function analysis - application and interpretation. V2.0/07.2007. Dynabyte Medical, Monachium 2007
25. Vaidyula VR, Boden G, Rao AK (2006) Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 17:577-585
26. Labuz-Roszak B, Pierzchala K, Machowska-Majchrzak A, Porosinska A, Wawrzynczyk M (2010) Evaluation of platelet function in patients taking acetylsalicylic acid as a secondary stroke prevention. Ann Acad Med Siles 64:54-63
27. Friend M, Vucenik I, Miller M (2003) Platelet responsiveness to aspirin in patients with hyperlipidemia. BMJ 326:82-83
28. Awtry EH, Loscalza J (2000) Aspirin. Circulation 101:1026-1218
29. Schror K (1997) Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23:349-356
30. Dutch TIA Trial Study Group (1991) A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack of minor ischemic stroke. N Engl J Med 325:1261-1266
31. Macchi L, Christaens L, Brizard A et al (2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107:5-49
32. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J (2004) Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35:175-178
33. Santilli F, Vazzana N, Liani R, Guagnano MT, Davì G (2012) Platelet activation in obesity and metabolic syndrome. Obes Res 13:27-42
34. Hung J, Lam JYT, Lacoste L et al (1995) Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92:2432-2436
35. Davis JW, Hartman CR, Lewis HD et al (1985) Cigarette smoking induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 105:479-483
36. Gum PA, Kottke-Marchand K, Poggio ED et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235
37. Cipollone F, Ciabattoni G, Patrono C et al (2000) Oxidant stress and aspirin-insensitive tromboxane synthesis in severe unstable angina. Circulation 102:1007-1013
38. Porosińska A, Pierzchala K (2006) Aspirin resistance theory. Neurol Neurochirur Pol 40:313-319
39. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43:979-984
40. Roller RE, Dorr A, Ulrich S, Pilger E (2002) Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagulat Fibrynol 13:277-281
41. Chen WH, Cheng X, Lee PY et al (2007) Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120:631-635
42. Li L, Han JL, Li HY et al (2012) Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction (abstract). Zhonghua Yi Xue Za Zhi 92:2677-2680
43. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157:148-153
44. Canella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooksygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809-1817
45. Kurth T, Glynn RJ, Walker AM et al (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 108:1191-1195
46. Hergovich N, Aigner M, Eichler HG, Drucker C, Jilma B (2000) Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 68:435-442
47. Siller-Matula JM, Lang IM, Christ G, Jilma B (2008) Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52:1557-1563
48. Tirnaksiz E, Pamukcu B, Oflaz H, Nisanci Y (2009) Effect of high dose statin therapy on platelet function; statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 27:24-28
49. Kenneth A, Schwartz L, Schwartz DE, Barber K, Reeves M, De Franco AC (2008) Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Trans Med 6:46-52